KALARIS THERAPEUTICS, INC. Investment Income, Interest
KALARIS THERAPEUTICS, INC. (KLRS) reported Investment Income, Interest of $5.49 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-07.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeInterest · last filed 2025-03-07
- KALARIS THERAPEUTICS, INC. investment income, interest for the quarter ending 2024-12-31 was $1.39M, a 1.02% increase year-over-year.
- KALARIS THERAPEUTICS, INC. investment income, interest for the quarter ending 2024-09-30 was $1.49M, a 1.84% decline year-over-year.
- KALARIS THERAPEUTICS, INC. investment income, interest for the quarter ending 2024-06-30 was $1.36M, a 10.29% decline year-over-year.
- KALARIS THERAPEUTICS, INC. investment income, interest for the quarter ending 2024-03-31 was $1.25M, a 5.96% decline year-over-year.
- KALARIS THERAPEUTICS, INC. investment income, interest for fiscal 2024 was $5.49M, a 4.33% decline from fiscal 2023.
- KALARIS THERAPEUTICS, INC. investment income, interest for fiscal 2023 was $5.73M, a 205.65% increase from fiscal 2022.
- KALARIS THERAPEUTICS, INC. investment income, interest for fiscal 2022 was $1.88M, a 42.66% increase from fiscal 2021.
- KALARIS THERAPEUTICS, INC. investment income, interest for fiscal 2021 was $1.31M, a 1.13% decline from fiscal 2020.
| Period end | Investment Income, Interest 3 month | Investment Income, Interest 6 month | Investment Income, Interest 9 month | Investment Income, Interest 12 month |
|---|---|---|---|---|
| 2024-12-31 | $1.39M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-07 | $2.88M derived: sum of 2 quarters · filed 2025-03-07 | $4.24M derived: sum of 3 quarters · filed 2025-03-07 | $5.49M 10-K · filed 2025-03-07 |
| 2024-09-30 | $1.49M 10-Q · filed 2024-11-12 | $2.85M derived: sum of 2 quarters · filed 2024-11-12 | $4.10M 10-Q · filed 2024-11-12 | $5.47M derived: sum of 4 quarters · filed 2025-03-07 |
| 2024-06-30 | $1.36M 10-Q · filed 2024-08-09 | $2.61M 10-Q · filed 2024-08-09 | $3.98M derived: sum of 3 quarters · filed 2025-03-07 | $5.50M derived: sum of 4 quarters · filed 2025-03-07 |
| 2024-03-31 | $1.25M 10-Q · filed 2024-05-13 | $2.62M derived: sum of 2 quarters · filed 2025-03-07 | $4.14M derived: sum of 3 quarters · filed 2025-03-07 | $5.66M derived: sum of 4 quarters · filed 2025-03-07 |
| 2023-12-31 | $1.37M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-07 | $2.89M derived: sum of 2 quarters · filed 2025-03-07 | $4.41M derived: sum of 3 quarters · filed 2025-03-07 | $5.73M 10-K · filed 2025-03-07 |
| 2023-09-30 | $1.52M 10-Q · filed 2024-11-12 | $3.04M derived: sum of 2 quarters · filed 2024-11-12 | $4.36M 10-Q · filed 2024-11-12 | $5.26M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $1.52M 10-Q · filed 2024-08-09 | $2.84M 10-Q · filed 2024-08-09 | $3.74M derived: sum of 3 quarters · filed 2024-08-09 | $4.41M derived: sum of 4 quarters · filed 2024-08-09 |
| 2023-03-31 | $1.32M 10-Q · filed 2024-05-13 | $2.22M derived: sum of 2 quarters · filed 2024-05-13 | $2.89M derived: sum of 3 quarters · filed 2024-05-13 | $3.05M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $898.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | $1.57M derived: sum of 2 quarters · filed 2024-03-15 | $1.73M derived: sum of 3 quarters · filed 2024-03-15 | $1.88M 10-K · filed 2024-03-15 |
| 2022-09-30 | $668.00K 10-Q · filed 2023-11-02 | $830.00K derived: sum of 2 quarters · filed 2023-11-02 | $978.00K 10-Q · filed 2023-11-02 | $1.06M derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-06-30 | $162.00K 10-Q · filed 2023-08-03 | $310.00K 10-Q · filed 2023-08-03 | $392.00K derived: sum of 3 quarters · filed 2023-08-03 | $645.00K derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $148.00K 10-Q · filed 2023-05-04 | $230.00K derived: sum of 2 quarters · filed 2023-05-04 | $483.00K derived: sum of 3 quarters · filed 2023-05-04 | $958.00K derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $82.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-15 | $335.00K derived: sum of 2 quarters · filed 2023-02-15 | $810.00K derived: sum of 3 quarters · filed 2023-02-15 | $1.31M 10-K · filed 2023-02-15 |
| 2021-09-30 | $253.00K 10-Q · filed 2022-11-03 | $728.00K derived: sum of 2 quarters · filed 2022-11-03 | $1.23M 10-Q · filed 2022-11-03 | $1.83M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $475.00K 10-Q · filed 2022-08-04 | $980.00K 10-Q · filed 2022-08-04 | $1.57M derived: sum of 3 quarters · filed 2022-08-04 | $1.69M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $505.00K 10-Q · filed 2022-05-05 | $1.10M derived: sum of 2 quarters · filed 2022-05-05 | $1.21M derived: sum of 3 quarters · filed 2022-05-05 | $1.38M derived: sum of 4 quarters · filed 2022-05-05 |
| 2020-12-31 | $595.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-10 | $707.00K derived: sum of 2 quarters · filed 2022-02-10 | $873.00K derived: sum of 3 quarters · filed 2022-02-10 | $1.33M 10-K · filed 2022-02-10 |
| 2020-09-30 | $112.00K 10-Q · filed 2021-11-05 | $278.00K derived: sum of 2 quarters · filed 2021-11-05 | $735.00K 10-Q · filed 2021-11-05 | $1.40M derived: sum of 4 quarters · filed 2021-11-05 |
| 2020-06-30 | $166.00K 10-Q · filed 2021-08-06 | $623.00K 10-Q · filed 2021-08-06 | $1.29M derived: sum of 3 quarters · filed 2021-08-06 | $2.07M derived: sum of 4 quarters · filed 2021-08-06 |
| 2020-03-31 | $457.00K 10-Q · filed 2021-05-06 | $1.12M derived: sum of 2 quarters · filed 2021-05-06 | $1.90M derived: sum of 3 quarters · filed 2021-05-06 | $2.41M derived: sum of 4 quarters · filed 2021-05-06 |
| 2019-12-31 | $665.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-12 | $1.45M derived: sum of 2 quarters · filed 2021-02-12 | $1.95M derived: sum of 3 quarters · filed 2021-02-12 | $2.06M 10-K · filed 2021-02-12 |
| 2019-09-30 | $781.00K 10-Q · filed 2020-11-10 | $1.28M derived: sum of 2 quarters · filed 2020-11-10 | $1.40M 10-Q · filed 2020-11-10 | |
| 2019-06-30 | $503.00K 10-Q · filed 2020-09-02 | $619.00K 10-Q · filed 2020-09-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |